Skip to content

Responses to Appetite and Taste in the Brain Circuits That Control Eating Behaviour

Responses to Appetite and Taste in the Brain Circuits That Control Eating Behaviour: An fMRI Study Evaluating Brain Structure, Connectivity and Responses to Taste Across Different Body Weight Categories and in Response to Weight Loss

Status
Suspended
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03547063
Acronym
TASTER
Enrollment
75
Registered
2018-06-06
Start date
2018-12-18
Completion date
2022-12-31
Last updated
2021-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Obesity, appetite, taste, fMRI

Brief summary

The aim of this study is to gain insight into brain structure and the neural networks that control taste and eating behaviour in patients with severe obesity undergoing a primary sleeve gastrectomy (SG) or a lifestyle intervention for weight loss compared with normal weight individuals, using functional magnetic resonance imaging (fMRI).

Detailed description

This is an observational study aiming to gain insight into brain structure and the neural networks that control taste and eating behaviour in patients with severe obesity undergoing a primary sleeve gastrectomy (SG) or a lifestyle intervention for weight loss compared with normal weight individuals using functional magnetic resonance imaging (fMRI). Drops of liquid foods and a control solution will be delivered to the participants' mouth during fMRI scanning. Body weight, gut hormones from serial blood samples, appetite scores and taste will be assessed at each study visit.

Interventions

None listed

Sponsors

University College, London
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Female and male adults aged 18-50 years. * Right-handed. * No MRI contra-indications. * Weight stable at time of recruitment, defined as less than 5% variation in body weight over the preceding 3 months. * Proficient in written and spoken English. * Able to comply with study protocol. * Willing and able to provide written informed consent. * Participants must be registered with a general practitioner (GP). * Willing for their treating consultant or their GP and the study team to be informed in the event of an incidental abnormal finding being detected by the investigations or assessments that form part of this study. * Able to lie flat for 1 hour. Group-specific inclusion criteria: * SG group: * BMI of 35-50 kg/m2 * Planned to undergo primary SG surgery and fulfilling eligibility criteria for bariatric surgery. * Lifestyle intervention group: * BMI of 35-50 kg/m2 * Willing to undergo a lifestyle intervention programme with a view to achieving approximately 10% weight loss. * Normal weight group: * BMI 18.5-24.9 kg/m2

Exclusion criteria

* Body weight greater than 130kg (due to weight limit of MRI Scanner). * Contraindications specific to MRI scanning: metallic implants (cardiac pacemakers, aneurysm clips, permanent eye lining, cochlear implants or anyone who has been exposed to metallic flakes or splinters). * Type 1 and type 2 diabetes (in view of altered circulated gut hormone profiles and gustatory function). * Menopause (in view of findings that the menopause affects gustatory function). * Smoking (in view of the fact that smoking affects salivary gut hormones and gustatory function). * Vitamin B12 or zinc deficiency (in view of deficiencies affecting gustatory function). * Untreated severe depression. * Eating disorders including bulimia and self-induced vomiting. * Neurological or psychiatric conditions. * Acute illness or chronic conditions that may impact upon gustatory and olfactory function. * Acute illness or chronic conditions that may impact upon post-operative weight loss. * Known or suspected history of HIV, Hepatitis B or C or other blood-borne diseases (in view of safety regulations regarding exposure to blood products) * Pregnancy or lactation.

Design outcomes

Primary

MeasureTime frameDescription
BOLD signal change after SGapproximately 6 weeksTo determine the effect of SG, at 10% weight loss, upon whole-brain neural response to taste, in the fed and fasted state, detected through blood-oxygen-level dependent (BOLD) signal, in patients with severe obesity.

Secondary

MeasureTime frameDescription
BOLD signal in response to taste in severe obesity compared to normal weightbaselineBrain responses, as BOLD signal, to taste in the fed and fasted state in severe obesity compared to normal weight
BOLD signal change post-SG6 monthsWhole brain neural response in BOLD signal to taste, in the fed and fasted state, 6 months following SG versus normal weight
Correlation of taste responses and gut hormonesbaselineThe relationship between the neural correlates of taste and levels of circulating gut hormones in severe obesity compared to normal weight
BOLD signal change after lifestyle interventionaverage of 12 weeksThe effect of 10% weight loss in patients with severe obesity induced by a lifestyle intervention on BOLD signal to taste in the fed and fasted state and compared to SG.
Brain structure 6 months following SG6 monthsComparison of brain structure 6 months following SG to baseline
Brain structure after 10% weight lossapproximately 6 weeks for SG group and approximately 12 weeks for lifestyle intervention groupComparison of brain structure following 10% weight loss induced by SG versus lifestyle intervention
Brain structureBaselineComparison of brain structure in severe obesity and normal weight

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026